Cagrilintide vs Sermorelin
Extensively Studied vs Well Studied
synergistic Mechanism-based · 51% Cagrilintide helps counteract the insulin-disrupting effects of Sermorelin. A smart combination — the insulin sensitizer mitigates metabolic side effects.
Molecular Data
Cagrilintide Sermorelin
Weight 4,409.01 Da 3,358 Da
Half-life ~7 days (159-195 hours) 10-12 minutes
Chain 37 amino acids 29 amino acids
Type Amylin receptor agonist GHRH analog
Key Benefits
Cagrilintide
01 FDA development candidate with extensive Phase 3 data
02 Superior weight loss in combination with semaglutide (22.7%)
03 Once-weekly convenience
04 2.2% HbA1c reduction with CagriSema
Sermorelin
01 FDA-proven efficacy
02 Maintains natural GH pulsatile patterns
03 Preserves pituitary function
04 1.26kg lean mass increase documented in elderly
05 IGF-1 mediated anabolic effects
06 Allows natural feedback regulation
Dosing Protocols
Cagrilintide
2.4mg weekly (after escalation) / Once weekly, same day each week
Weight Loss (Monotherapy) 2.4mg Once weekly
Weight Loss (CagriSema) 2.4mg + semaglutide 2.4mg Once weekly
Type 2 Diabetes Management 2.4mg weekly Once weekly
Dose Escalation Protocol 0.25mg → 0.5mg → 1.0mg → 1.7mg → 2.4mg Weekly increases over 16 weeks
Sermorelin
200-300mcg per dose (up to 500mcg for athletic performance) / Once daily at bedtime (aligns with natural GH pulse)
Anti-aging/Longevity 200-300mcg Once at bedtime
Athletic Performance 300-500mcg Once at bedtime
Body Composition 200mcg 5 days weekly
Combination Therapy 200mcg + GHRP Once daily
Side Effects
Cagrilintide
Gastrointestinal effects (nausea, vomiting, diarrhea) during initial weeks
Anti-cagrilintide antibodies develop in 46-73% but do not affect efficacy
Only 57.3% achieved maximum 2.4mg dose in REDEFINE 1 trial
Sermorelin
Injection site reactions (16.7% of patients - generally mild)
Nasal irritation (intranasal route)
Contraindications
Not recommended in pregnancy or breastfeeding
Not yet commercially available (FDA approval expected Q1 2026)
Active malignancy
Pituitary tumors
Pregnancy
Research Evidence
Cagrilintide Sermorelin
Status Extensively Studied Well Studied
References 3 studies 5 studies
Latest December 2025 November 2024
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.